Cyclerion Therapeutics
CYCN
18 hedge funds and large institutions have $4.1M invested in Cyclerion Therapeutics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 11 reducing their positions, and 18 closing their positions.
39.13% more ownership
Funds ownership: 2.37% → 41.5% (+39%)
47% less funds holding
Funds holding: 34 → 18 (-16)
54% less capital invested
Capital invested by funds: $8.95M → $4.1M (-$4.85M)
73% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 11
89% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$69.2K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$4.34K |
| 3 |
Morgan Stanley
New York
|
+$1.15K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$570 |
| 5 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$114 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$50.1K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$49.9K |
| 3 |
CG
Colony Group
Boston,
Massachusetts
|
-$44K |
| 4 |
Renaissance Technologies
New York
|
-$38K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$35.1K |
CYCN Hedge Fund Activity: Q2 2023 in Review
18 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q2 2023, worth a combined $4.1M — down 54% from $8.95M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of CYCN and 2 opened new positions — a net loss of 16 holders — while 11 trimmed existing stakes and 3 added.
The largest buyer was Jane Street, opening a new position worth an estimated $69.2K. The largest seller was State Street, exiting entirely with an estimated $50.1K sold.
- 18 institutional investors held Cyclerion Therapeutics (CYCN) as of Q2 2023, down from 34 in Q1 2023.
- Funds reported $4.1M of Cyclerion Therapeutics stock for Q2 2023, down 54% quarter-over-quarter.
- 2 funds opened new Cyclerion Therapeutics positions in Q2 2023 and 18 closed out, a net change of -16 holders.
- The largest Cyclerion Therapeutics buyer in Q2 2023 was Jane Street, an estimated $69.2K added.
- The largest Cyclerion Therapeutics seller in Q2 2023 was State Street, an estimated $50.1K sold.
Based on aggregated 13F filings for Q2 2023.